Abstract: The invention relates to compounds of Formula (I), (Ia), (Ib), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.

Abstract: Disclosed herein is a method for treating and/or minimize injection site reactions (ISRs) and/or preventing severe ISRs in a subject in need thereof by admixing, co-formulating or co-administering a steroid composition. In some embodiments, this disclosure is directed to a method for treating a central nervous system (CNS) disorder. The method comprises co-administering a steroid composition and a neuroactive steroid (NAS). The method can be used for preventing and/or treating CNS conditions or diseases related to GABA-modulation, such as depression, postpartum depression (PPD) particularly in lactating women, bipolar disorder, dementia, Huntington's disease, Parkinson's disease, and other diseases, and preventing severe ISRs.

Abstract: A method of treating HIV comprising intramuscular administration once every 4 weeks or less frequently of a combination of cabotegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof, including the option of discontinuing administration of a first oral anti-retroviral regimen and intramuscularly administering, once four weeks or less often said combination of cabotegravir and rilpivirine.

Abstract: A method of treating HIV comprising intramuscular administration once every 4 weeks or less frequently of a combination of cabotegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof, including the option of discontinuing administration of a first oral anti-retroviral regimen and intramuscularly administering, once four weeks or less often said combination of cabotegravir and rilpivirine.

Abstract: The invention relates to compounds of Formula (I), salts thereof, combinations, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.

Abstract: Disclosed are composite filaments for 3D printing. The filaments typically have high strength, an appropriate resorption rate, and high biocompatibility. The filaments generally contain a matrix formed of a blend containing a bioresorbable polymer and an inorganic component. The filaments can be used to produce customized scaffolds for repairing bone defects following implantation in the site of the defect. The shape and size of the scaffold can be configured to fit in and conform to the bone defect. The scaffolds are especially useful in repairing critical sized bone defect, such as a critical sized bone defect in a weight-bearing long bone.

Abstract: The invention relates to compounds of Formula (I), (Ia), (Ib), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.

Abstract: The invention relates to compounds of Formula (I), salts thereof, combinations, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.

Abstract: The invention relates a compound of the formula: a pharmaceutically acceptable salt thereof, compositions thereof, and methods of therapeutic treatment using the same.

Abstract: The invention relates a compound of the formula: a pharmaceutically acceptable salt thereof, compositions thereof, and methods of therapeutic treatment using the same.

Abstract: A method of treating HIV comprising intramuscular administration once every 4 weeks or less frequently of a combination of cabotegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof, including the option of discontinuing administration of a first oral anti-retroviral regimen and intramuscularly administering, once four weeks or less often said combination of cabotegravir and rilpivirine.

Abstract: Digital obsolescence avoidance systems and methods may determine an obsolescence vulnerability for a digital object. A digital obsolescence avoidance system may include a validation system and an obsolescence vulnerabilities system. The validation system may be configured to receive metadata for the digital object and to determine a digital object kind for the received metadata. The obsolescence vulnerabilities system may be configured to determine one or more dependencies for the determined object kind, to determine an obsolescence vulnerability based on the determined one or more dependencies, and to provide output related to the determined obsolescence vulnerability.

Abstract: Digital obsolescence avoidance systems and methods may determine an obsolescence vulnerability for a digital object. A digital obsolescence avoidance system may include a validation system and an obsolescence vulnerabilities system. The validation system may be configured to receive metadata for the digital object and to determine a digital object kind for the received metadata. The obsolescence vulnerabilities system may be configured to determine one or more dependencies for the determined object kind, to determine an obsolescence vulnerability based on the determined one or more dependencies, and to provide output related to the determined obsolescence vulnerability.

Abstract: This invention relates to a treatment of acne. Specifically, the invention is directed to the use of bacteriocin-like inhibitory substances (BLIS), isolated from S. salivarius as bacteriocide or bacteriostat for acne-causing bacteria, namely P. acnes.

Abstract: This invention relates to a treatment of acne. Specifically, the invention is directed to the use of bacteriocin-like inhibitory substances (BLIS), isolated from S. salivarius as bactericide or bacteriostat for acne-causing bacteria, namely P. acnes.

Abstract: This invention relates to a treatment of acne. Specifically, the invention is directed to the use of bacteriocin-like inhibitory substances (BLIS), isolated from S. salivarius as bactericide or bacteriostat for acne-causing bacteria, namely P. acnes.

Abstract: An integrative DNA vector and one or more viral proteins having affinity for DNA are packaged in cochleate precipitates. The integrative DNA vector contains one or more therapeutic nucleotide sequences that are preferably positioned between DNA substrates for the proteins. Upon contact with a lipid bilayer of a target cell, the cochleate vector structure delivers one or more of the therapeutic nucleotide sequences and one or more proteins to the interior of the target cell. Upon entry into the cell, the proteins facilitate the integration of the therapeutic nucleotide sequence into the genome of the host cell.

Abstract: Synergistic combinations of guanosine nucleoside analog reverse transcriptase inhibitors such as abacavir with inosine monophosphate dehydrogenase inhibitors such as mycophenolates, pharmaceutical compositions comprising such combinations, and therapeutic methods comprising administering the synergistic combinations to subjects in need thereof, for treating a viral infection, such as an HIV-1 infection.

Abstract: A method of calculating a complex node representation for logical nodes in a hierarchical peer group in a PNNI based ATM network. The summary information for default spokes, exceptions and bypasses is determined in a way that closely represents the underlying metrics associated with the peer group. A list of all border nodes in the peer group is generated and maintained and a matrix of tables is generated, one table for each metric per each class of service. The table is populated by the best value associated with the corresponding metric for a particular pair of border nodes within a particular class of service. Once the table is populated, each element is placed in a group or bin. The bins are generated by dividing the full range of the metric into a plurality of smaller subgroups or bins. The bin having a count greater than a threshold count is selected and 80% of the worst value for that group is used as the default spoke.

Abstract: An integrative DNA vector and one or more viral proteins having affinity for DNA are packaged in cochleate precipitates. The integrative DNA vector contains one or more therapeutic nucleotide sequences that are preferably positioned between DNA substrates for the proteins. Upon contact with a lipid bilayer of a target cell, the cochleate vector structure delivers one or more of the therapeutic nucleotide sequences and one or more proteins to the interior of the target cell. Upon entry into the cell, the proteins facilitate the integration of the therapeutic nucleotide sequence into the genome of the host cell.